A cost-effectiveness analysis of pneumococcal vaccination in street-involved, HIV-infected patients

Canadian Journal of Public Health

Volumn 91, Issue 5, 2000, Pages 334-339

  Marra, C A ^a   Patrick, D M ^a   Marra, F ^a  

^a VANCOUVER HOSPITAL AND HEALTH SCIENCES CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CD4 ANTIGEN; COTRIMOXAZOLE; PNEUMOCOCCUS VACCINE;

ARTICLE; CANADA; COHORT ANALYSIS; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; GOVERNMENT; HEALTH CARE COST; HEALTH CARE DELIVERY; HEALTH CENTER; HEALTH PROGRAM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MEDICAL DECISION MAKING; MORBIDITY; MORTALITY; PATIENT COMPLIANCE; PRESCRIPTION; PUBLIC HEALTH SERVICE; SIDE EFFECT; STREPTOCOCCUS INFECTION; TREATMENT OUTCOME; VACCINATION;

EID: 0033646694     PISSN: 00084263     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03404802     Document Type: Article

References (34)

1. Pneumococcal disease during HIV infection: Epidemiologic, clinical and immunologic perspectives
2. Bacterial infections in adult patients with the acquired immune deficiency syndrome (AIDS) and AIDS-related complex
3. Bacterial pneumonia in patients with the acquired immune deficiency syndrome
4. Bacterial pneumonia in persons infected with the human immunodeficiency virus
5. Pneumococcal pneumonia in adult hospitalized patients infected with the human immunodeficiency virus
6. Use of surveillance for invasive pneumococcal disease to estimate the size of the immunosuppressed HIV-infected population
7. The role of human immunodeficiency virus infection in pneumococcal bacteremia in San Francisco residents
8. Epidemiologic relation between HIV and invasive pneumococcal disease in San Francisco County, California
9. Streptococcus pneumoniae colonization, bacteremia, immune response among persons with human immunodeficiency virus
10. Prevention of pneumococcal disease. Recommendations of the Advisory Committee on Immunization Practices
11. Antibody response after influenza and pneumococcal immunization in HIV-infected homosexual men
12. Personnal communication
13. Barriers to receiving antiretroviral therapy among injection drug users
14. The use of consensus methods and expert panels in pharmacoeconomic studies. Practical applications and methodological short-comings
15. Considerations for formulating the second-generation pneumococcal capsular polysaccharide vaccine with emphasis on the cross-reactive types within groups
16. Pneumococcal polysaccharide vaccine efficacy: An evaluation of current recommendations
17. A controlled evaluation of the protective efficacy of pneumococcal vaccine for patients at high risk of serious pneumococcal infections
18. The clinical effectiveness of pneumococcal vaccine in the elderly
19. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine
20. Preventing pneumococcal bacteremia in patients at risk: Results of a matched case-control study
21. Streptococcus pneumoniae polysaccharide vaccine: Age and dose responses, safety, persistence of antibody, revaccination and simultaneous administration of pneumococcal and influenza vaccines
22. Pneumococcal antibodies (IgG, IgM) in patients with chronic obstructive lung disease 3 years after pneumococcal vaccination
23. Efficacy of pneumococcal vaccination in adults: A meta-analysis of randomised controlled trials
24. Handling uncertainty in economic evaluation
25. Pneumococcal immunization program in Monteregie Quebec: Feasibility study
26. Pneumococcal immunization program: Cost-utility analysis for Quebec
27. Preventing pneumococcal disease: A Canadian consensus conference
28. Cost-effectiveness of vaccination against pneumococcal pneumonia
29. A cost-benefit analysis of immunization for pneumococcal pneumonia
30. Pneumococcal vaccine efficacy and associated cost savings
31. Cost-effectiveness of vaccination against pneumococcal pneumonia: An update
32. Cost-effectiveness of vaccination against pneumococcal bacteremia among elderly people
33. Influenza and pneumococcal vaccination of HIV-infected patients: A policy analysis